An anti-CTLA-4 agent, Tremelimumab, was evaluated in a phase-III trial with 247 HNSCC patients, in comparison with the standard treatment regiment and Durvalumab, an anti-PDL1 agent [41]. Here, CTLA4 is linked to head and neck squamous cell carcinoma.